At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 54 enrolled
Drug / intervention
Bexagliflozin +3 moredrug
Likely dose
Bexagliflozin 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Randomized, Three-period, Crossover Study to Evaluate Pharmacokinetic Interaction Between Bexagliflozin Tablets and Metformin, Glimepiride, or Sitagliptin in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Bexagliflozin, Metformin, and 2 other interventions for Type2 Diabetes Mellitus. Completed, enrolled 54 participants across 1 site.
Detailed Summary
The purpose of this study is to examine the drug-drug interaction in your body when given the study drug, bexagliflozin, with three commonly used ant-diabetic medications, metformin, glimepiride or sitagliptin. The study will also evaluate how safe the study drug is and how well the study drug is tolerated when taken with metformin, glimepiride or sitagliptin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType2 Diabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedNov 2016
Primary CompletionMar 2017
TodayJul 2026
First PostedNov 4, 2016
Enrollment StartNov 1, 2016
Primary CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.7 years ago
Interventions
Bexagliflozindrug
Bexagliflozin tablets, 20 mg
Metformindrug
1000 mg metformin
Glimepiridedrug
4 mg glimepiride
Sitagliptindrug
100 mg sitagliptin